ClinicalTrials.gg
Not yet recruitingNCT07942766Updated Nov 17, 2026

A Study of HW201877 Capsules for Participants With Moderate to Severe Active Inflammatory Bowel Disease (IBD)

A Phase 2 interventional study of HW201877 capsules in Inflammatory Bowel Disease (IBD), sponsored by Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. · Phase 2, Interventional, and Treatment

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 114 studies in Inflammatory Bowel Diseases with a site in China — 51 open to participants now, 55 under way, 5 of them phase 3. Inflammatory Bowel Diseases · China.

Planned enrollment
50th of 60
40 · median 97
Started
2026
with 9 others
Phase 2
9 of 114
4 open now
Primary completion
2027-12
later than 40 of 54 live
Registered
114th of 114
by date

Among the 114 studies in Inflammatory Bowel Diseases with a site in China, this one is the 50th largest by planned enrollment of the 60 interventional ones that give a count, is one of 10 that started in 2026, is one of 9 in phase 2, reaches primary completion later than 40 of the 54 other live ones, and was the 114th registered.

Inflammatory Bowel Diseases

1,550 studies on the registry are indexed under Inflammatory Bowel Diseases; 423 are open to participants now.

Browse Inflammatory Bowel Diseases studies →

Open to participants now

51 of the 114 studies in Inflammatory Bowel Diseases with a site in China are open now. Recruiting first, the newest first:

46 more — sign in →

All 51 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 276 Inflammatory Bowel Diseases studies recruiting now, 133 (48%) set no upper age limit and 116 (42%) stop at 75 or younger; 76 take children under 18; 61 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 114 studies in Inflammatory Bowel Diseases with a site in China, or all of them as a file.
02

Study summary

This is a Phase IIa, open-label, multicenter clinical trial that plans to enroll approximately 20 patients each with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD) who have had an inadequate response, loss of response, or intolerance to prior therapies. Participants will receive 12 weeks of the investigational study drug to provide a preliminary assessment of its efficacy and safety.

03

Conditions studied

  • Inflammatory Bowel Disease (IBD)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 to 75 years (inclusive).
  • (BMI) ≥18 kg/m\^2 at screening.
  • Participants must have been diagnosed with ulcerative colitis or Crohn's disease at least 3 months prior to the start of screening, and confirmed by endoscopy and histology at screening.
  • Meeting one of the criteria for moderate to severe active disease.
  • Participants have had an inadequate response, loss of response, or intolerance to at least one conventional therapy and/or advanced therapy, or are unable to receive these treatments for other reasons.
  • Female participants of must have a negative pregnancy test and must not be breastfeeding; male and female participants must not plan to become pregnant or father a child throughout the clinical study period and for 3 months after the last dose, and must agree to use medically accepted reliable methods during the study period and for 3 months after the last dose.
  • Fully understand the study, voluntarily sign the form, and be able to comply with the study procedures and follow-up examination requirements.

Exclusion criteria

Exclusion Criteria:

  • Presence of any of the following cohort-specific conditions (as applicable to the enrolled cohort):

Cohort 1 (UC patients): Ulcerative colitis with rectal involvement only (disease extent limited to within 10 cm from the anal verge); Cohort 2 (CD patients): Presence of fistulas (excluding perianal fistulas), perianal abscess (except those without active symptoms after incision and drainage), extensive small bowel resection (>100 cm), or short bowel syndrome, where efficacy cannot be assessed by CDAI/SES-CD.

  • Evidence of or clinical suspicion of other active gastrointestinal inflammatory diseases including: indeterminate colitis (IBDU), intestinal Behçet's disease, colitis ischaemic, radiation colitis, drug-induced enteropathy, enteritis infectious, diverticulitis-associated colitis, etc.
  • Presence of symptomatic intestinal strictures (including those with pre-stenotic dilation and obstructive symptoms), abdominal abscess, fulminant colitis and toxic megacolon, intestinal perforation.
  • Participants who have previously undergone intestinal surgery or who may require surgical treatment during the study (including but not limited to: colostomy/ileostomy, total proctocolectomy, partial colectomy).
  • Long-term exclusive enteral nutrition or parenteral nutrition prior to screening.
  • Endoscopic findings at screening revealing gastrointestinal dysplasia (atypical hyperplasia)/cancer, except for completely resected low-grade dysplasia.
  • Active Clostridium difficile infection or other active intestinal infection within 30 days prior to baseline assessment; or positive Clostridium difficile toxin assay or other enteric pathogen screening within 30 days prior to baseline assessment with infection-related clinical symptoms, except for simple intestinal colonization (without evidence of infection).
  • Participants who currently have or have a history of any of the following infections:

    1. infection within 1 month prior to screening;
    2. Any infection requiring antimicrobial therapy within 2 weeks prior to screening;
    3. Any other history of infection that the investigator believes may be exacerbated by participation in this study.
  • Based on interferon-gamma release assay (e.g., QuantiFERON®-TB Gold test, T-SPOT®.TB, etc.) results, clinical symptoms, and/or chest imaging findings, the participant is judged to possibly have active Mycobacterium tuberculosis (TB) infection.
  • At screening, positive test results, positive Virus Antibody (HCV Ab), positive Antibody (HIV Ab), positive Treponema pallidum Antibody (TP Ab).
  • Any congenital or acquired immunodeficiency (e.g., HIV infection, organ transplantation, etc.)
  • Use of any drug or therapeutic measure prohibited by the protocol.
  • within 5 years prior to screening (except locally excised non-melanoma skin cancer and radically treated cervical carcinoma in situ); existing non-melanoma skin cancer must be excised prior to enrollment.
  • Any significant laboratory finding will result in exclusion from the study.
  • Clinically significant abnormalities, such as prolongation (male > 450 ms, female > 470 ms) (QTcF = QT/(RR\^0.33)), long QT syndrome, etc.
  • History of moderate to severe cardiac failure congestive ( [NYHA] functional class ≥ III), cerebrovascular or cardiovascular events, or severe bleeding events within 3 months prior to screening, which in the investigator's judgment makes the participant unsuitable for participation in the clinical study.
  • Severe, progressive, or uncontrolled cardiovascular, cerebrovascular, hepatic, renal, pulmonary, gastrointestinal, ophthalmic, hematopoietic, endocrine, neurological, psychiatric, or other abnormalities that, in the investigator's assessment, make the participant unsuitable for enrollment in this study.
  • Pregnant or breastfeeding (pregnancy is defined as the state from conception until termination of pregnancy).
  • Allergy to the product or any ingredient in the investigational product.
  • History of alcohol abuse (consumption of 14 units of alcohol per week: 1 unit = 285 mL of beer, or 25 mL of spirits, or 100 mL of wine) or drug abuse within one year prior to screening.
  • Total blood donation exceeding 500 mL within 8 weeks prior to the first dose, or planned blood donation during the study period.
  • Conditions that, in the investigator's judgment, may affect the safety and efficacy evaluation of the investigational product.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    HW201877

    Drug: HW201877 capsules

Interventions

  • DrugHW201877 capsules

    HW201877 oral capsule,12W

06

What researchers measure

Primary outcomes

  1. Cohort 1 • Proportion of participants achieving clinical remission based on the modified Mayo score at Week 12;

    Time frame: At week 12

  2. Cohort 2 Co-primary endpoints: • Proportion of participants achieving symptomatic remission at Week 12;

    Time frame: At week 12

  3. Cohort 2 Co-primary endpoints: • Proportion of participants achieving endoscopic response at Week 12.

    Time frame: At week 12

Secondary outcomes

  1. Cohort 1 • Proportion of participants achieving endoscopic response at Week 12;

    Time frame: at week 12

  2. Cohort 1 • Proportion of participants achieving histologic remission at Week 12;

    Time frame: at week 12

  3. Cohort 2 • Proportion of participants achieving symptomatic response at each visit;

    Time frame: at week 12

  4. Cohort 2 • Change from baseline in CDAI score at each visit;

    Time frame: at week 12

  5. Cohort 2 • Change from baseline in total score of Inflammatory Bowel Disease Questionnaire (IBDQ) at each visit.

    Time frame: at week 12

  6. Safety Endpoints • Incidence of AEs and SAEs during the study;

    Time frame: at week 12

  7. Safety Endpoints • Incidence of discontinuation of study treatment due to AEs and SAEs during the study;

    Time frame: at week 12

  8. Safety Endpoints • Incidence of AEs and SAEs leading to withdrawal from the study during the study;

    Time frame: at week 12

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Dec 2027, 13 months later.

Of 61 phase 2 interventional studies under Inflammatory Bowel Diseases, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 43. This study's planned 13 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2026
First posted
Nov 17, 2026
StartEst.
Nov 2026
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07942766
Lead sponsor
Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Nov 2026 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Lifei Liu
Contact
liulifei@renfu.com.cn
86-27-87173753

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion